MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Начало・Списък с акции・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Затворен

СекторЗдравеопазване

29.04 3.68

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

28.27

Максимум

29.64

Ключови измерители
By Trading Economics
Приходи	23M 7.4M
Продажби	18M 99M
EPS	0.06
Марж на печалбата	7.468
Служители	342
EBITDA	23M 11M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+5.92% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.1B 3.5B
Предишно отваряне	25.36
Предишно затваряне	29.04

Настроения в новините

By Acuity

47%

53%

148 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

12.42 / 14.93 Подкрепа & съпротива

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.12.2025 г., 22:20 ч. UTC

Значими двигатели на пазара

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31.12.2025 г., 17:31 ч. UTC

Значими двигатели на пазара

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31.12.2025 г., 16:30 ч. UTC

Значими двигатели на пазара

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31.12.2025 г., 15:19 ч. UTC

Значими двигатели на пазара

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31.12.2025 г., 15:17 ч. UTC

Значими двигатели на пазара

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31.12.2025 г., 14:37 ч. UTC

Значими двигатели на пазара

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

31.12.2025 г., 21:13 ч. UTC

Придобивния, сливания и поглъщания

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31.12.2025 г., 20:40 ч. UTC

Пазарно говорене

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31.12.2025 г., 20:22 ч. UTC

Пазарно говорене

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31.12.2025 г., 19:50 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31.12.2025 г., 19:31 ч. UTC

Пазарно говорене

Precious Metals Cap Off Record Runs -- Market Talk

31.12.2025 г., 18:50 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

31.12.2025 г., 18:50 ч. UTC

Пазарно говорене

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31.12.2025 г., 17:17 ч. UTC

Пазарно говорене

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31.12.2025 г., 17:16 ч. UTC

Значими двигатели на пазара

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31.12.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

31.12.2025 г., 17:00 ч. UTC

Придобивния, сливания и поглъщания

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31.12.2025 г., 15:57 ч. UTC

Придобивния, сливания и поглъщания

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31.12.2025 г., 15:54 ч. UTC

Пазарно говорене

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31.12.2025 г., 15:02 ч. UTC

Значими двигатели на пазара

Nike Shares Rise After CEO Hill Buys $1M of Shares

31.12.2025 г., 14:40 ч. UTC

Придобивния, сливания и поглъщания

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31.12.2025 г., 14:20 ч. UTC

Пазарно говорене

Crude Futures On Track to End the Year With Losses -- Market Talk

31.12.2025 г., 13:46 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31.12.2025 г., 13:01 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31.12.2025 г., 11:10 ч. UTC

Пазарно говорене

Copper Remains in Touching Distance of Record Highs -- Market Talk

31.12.2025 г., 10:46 ч. UTC

Пазарно говорене

Euro on Track For Strong Annual Performance -- Market Talk

31.12.2025 г., 10:25 ч. UTC

Пазарно говорене

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31.12.2025 г., 10:23 ч. UTC

Пазарно говорене

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31.12.2025 г., 09:33 ч. UTC

Пазарно говорене

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

5.92% нагоре

12-месечна прогноза

Среден 30.25 USD 5.92%

Висок 37 USD

Нисък 21 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Arcutis Biotherapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

12.42 / 14.93Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bullish event.

Настроение

By Acuity

148 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.